Key facts
- Towa Pharmaceutical plans to start exporting generic injectable drugs to the US as early as 2028, its CEO said.
- Towa said it aims to use its quality control capabilities to enter the competitive US market.
- Towa gained a US sales network through its 2020 acquisition of a Spanish drugmaker.
Towa Pharmaceutical plans to start exporting generic injectable drugs to the US as early as 2028, its CEO said in a report published November 9, 2026. The Japanese drugmaker said it intends to use its quality control capabilities to gain a foothold in the competitive American market.
The company gained a US sales network through its 2020 acquisition of a Spanish drugmaker. Towa is also looking to shift toward high-value-added injectable drugs, according to the report.
The report did not name the CEO or give a volume, value or customer for the planned exports.